GlassScriptPhysician profile
Rhonda Quain Klein
NPI 1033386867
$4,672.80
in general payments reported to CMS, 2019-2025
34 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $821 · 2021: $499 · 2022: $556 · 2023: $1,060 · 2024: $468 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.08 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $665.52 | 2022-2025 | Opzelura |
| Abbvie INC. | $563.11 | 2019-2025 | |
| Janssen Biotech, INC. | $494.00 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $470.19 | 2019-2025 | Jublia, Cabtreo |
| Galderma Laboratories, L.P. | $241.23 | 2019-2023 | |
| Leo Pharma INC. | $226.93 | 2019-2022 | |
| Amgen INC. | $192.10 | 2020-2025 | Otezla |
| Genzyme Corporation | $187.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $166.65 | 2019-2023 | |
| Dermira, INC. | $153.51 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $136.30 | 2020-2023 | Libtayo |
| Mayne Pharma Commercial LLC | $130.60 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $115.66 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $115.60 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $108.92 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $106.60 | 2019-2021 | |
| Biofrontera INC. | $77.77 | 2019-2022 | |
| Merz North America, INC. | $77.15 | 2019-2025 | |
| Pfizer INC. | $60.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $48.06 | 2020-2021 | |
| Allergan, INC. | $42.49 | 2020-2021 | |
| Organon LLC | $39.55 | 2025 | |
| Ucb, INC. | $36.81 | 2022 | |
| Vyne Pharmaceuticals INC. | $34.51 | 2020 | |
| Medtronic Vascular, INC. | $27.15 | 2019 | |
| Blueprint Medicines Corporation | $24.14 | 2023 | |
| Encore Dermatology INC. | $18.94 | 2019 | |
| Botanix Sb INC | $18.77 | 2025 | Sofdra |
| Solta Medical, A Division of Bausch Health US, LLC | $18.53 | 2024 | Fraxel |
| Revance Therapeutics, INC. | $17.61 | 2024 | Daxxify |
| Merck Sharp & Dohme LLC | $16.93 | 2019 | |
| Dermavant Sciences, INC. | $15.48 | 2023 | Vtama |
| Glaxosmithkline, LLC. | $13.31 | 2023 | Arexvy, Shingrix |
| Prugen, INC. Pharmaceuticals | $10.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhonda Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.